Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Lauren Pinter-Brown, M.D., F.A.C.P.
Lauren Pinter-Brown, M.D., F.A.C.P.

Specialty:

Cancer/Medical Oncology
Hematology
Hematology/Oncology

General Information:

Gender:
Female
Language(s):
English, Spanish

Affiliation(s):

Clinical Professor, Department of Medicine, Hematology/Oncology
Director, UCLA Lymphoma Program
Member, JCCC Cancer and Stem Cell Biology Program Area

Education:

Fellowship:
Medicine, Hematology/Oncology, LAC+USC Medical Center, 1983 - 1986
Residency:
Internal Medicine, Harbor-UCLA Medical Center, 1981 - 1983
Internship:
Internal Medicine, Harbor-UCLA Medical Center, 1980 - 1981
Medical Degree:
M.D., UCLA School of Medicine, 1980

Certification(s):

Medical Board Certification(s):
Hematology, American Board of Internal Medicine, 1986
Medical Oncology, American Board of Internal Medicine, 1985
Internal Medicine, American Board of Internal Medicine, 1983

Contact Information:

Phone:
(310) 829-5471
Email:

Practice Information:

Clinical Interest(s):
Waldenstrom's Disease
Bone Marrow Transplantation
General Hematology
Lymphoma
Hodgkin Lymphoma
Follicular Lymphoma
Diffuse Large B-cell Lymphoma
Peripheral T-cell Lymphoma
Chronic Lymphocytic Leukemia
Hairy Cell Leukemia
Mycosis Fungoides

Scientific Interest(s):

Dr. Pinter-Brown is interested in optimizing treatment for patients diagnosed with lymphomas and is the principal investigator for clinical research protocols for patients with Hodgkin's disease, B-cell lymphomas, CD30+ Anaplastic large-cell lymphoma and T-cell lymphomas.

Selected Cancer-Related Publications:

Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007; 56(2): 317-26.

Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006; 91(6): 2205-8.

Emmanouilides C, Colovos C, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. Clin Lymphoma. 2004; 5(1): 45-9.

Roberts AA, Amano M, Felten C, Galvan M, Sulur G, Pinter-Brown L, Dobbeling U, Burg G, Said J, Baum LG. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol. 2003; 16(6): 543-51.